Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Quantinuum Inc (QNT)
NASDAQInformation TechnologyComputer HardwareSnapshot 2026-11-04
$32.75+0.55%
Close 2026-11-04 · 1-day change
NASDAQInformation TechnologyComputer HardwareSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for QNT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce operating losses | A supporting condition in Quantinuum Inc's published investment case. The stated target is operating losses below $500 million. | Intact | operating losses exceed $500 million | Operating income: $-555.026M FY2026-Q2; GAAP. Published target: operating losses below $500 million. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-555,026,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business in an early stage, not a proven compounder. Its long-term thesis is still insufficiently supported by recent financial history, and confidence in the overall evidence is low.
The evidence snapshot provides no valuation level or specific market expectations, so it is not possible to judge whether QNT is cheap, fair, or expensive versus peers. Fragility is marked low, but that does not establish what the market already assumes.
Near term, the company’s financial record remains difficult: it reported a $555 million operating loss and a $65 million net loss in 2026-Q2, and the snapshot notes recent earnings misses. Management has newly stated priorities around CHIPS-funded manufacturing, an Oracle partnership, and reducing losses, but there is not yet enough history to assess delivery.
Over the multi-year view, the key question is whether federal funding and the Oracle partnership help advance manufacturing and adoption of quantum computing. Near-term conditions also matter: Fed rate cuts and steadier technology-sector results could help the backdrop, while GDP growth slowing below 2% is identified as a risk.
The 1-to-3-year thesis remains early and uncertain, with promising strategic initiatives set against significant losses and limited evidence of execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Leverage $100 million CHIPS Act award for R&D |
| Quantinuum is advancing quantum computing with a $100 million CHIPS Act award. |
| Intact |
| fails to secure the full $100 million funding |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “Washington, D.C. – September 8, 2026 – Quantinuum (Nasdaq: QNT), a leading quantum computing company, today announced it has finalized an agreement with the U.S. Department of Commerce’s CHIPS Research and Development Office for $100 million in federal funding deployed through the CHIPS and Science Act.” “GlobalFoundries will be one of several of Quantinuum’s foundries enlisted to fabricate its next-generation ion traps and other electronics, specifically focused on using 300mm wafer technology; Monarch Quantum plans to develop and manufacture scalable, reliable lasers and optical components required for Quantinuum’s trapped-ion systems.” Revenue was $7.998 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Accelerate hybrid quantum compute adoption via partnerships | Strategic partnerships with companies like Oracle enhance growth potential. | Intact | fails to secure new partnerships | 2 partnerships vs >=2 target Oracle strategic partnership announced Aug 11, 2026; Aramco MoU signed Sep 7, 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.65 → $-1.56 · observed estimates
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-08 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-09 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-10 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-11 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-12 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-13 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-14 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-15 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-16 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-17 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-18 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-19 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-20 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-21 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-22 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-23 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-24 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-25 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-26 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-27 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-28 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-29 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-09-30 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-01 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-02 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-03 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-04 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-05 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-06 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-07 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-08 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-09 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-10 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-11 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-12 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-13 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-14 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-15 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-16 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-17 | $-1.65 | $61,150,000 | 7 / 8 |
| 2026-10-18 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-19 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-20 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-21 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-22 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-23 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-24 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-25 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-26 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-27 | $-1.65 | $61,180,000 | 7 / 9 |
| 2026-10-28 | $-1.56 | $61,180,000 | 7 / 9 |
| 2026-10-29 | $-1.56 | $61,180,000 | 7 / 9 |
| 2026-10-30 | $-1.56 | $61,180,000 | 7 / 9 |
| 2026-10-31 | $-1.56 | $61,180,000 | 7 / 9 |
| 2026-11-01 | $-1.56 | $61,180,000 | 7 / 9 |
| 2026-11-02 | $-1.56 | $61,180,000 | 7 / 9 |
| 2026-11-03 | $-1.56 | $61,180,000 | 7 / 9 |
| 2026-11-04 | $-1.56 | $61,180,000 | 7 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.